Latest studies
- RecruitingPhase II
A study to learn if ZED1227 can improve continued celiac disease symptoms despite a gluten-free diet
This study is testing a new capsule called ZED1227 for adults with coeliac disease. Researchers want to see if this medicine can protect the gut and ease lingering tummy symptoms caused by accidental gluten exposure, even in people who already follow a strict gluten-free diet.
Coeliac diseaseRomania - CompletedPhase III
A randomized, open-label phase 3 study of amivantamab + FOLFIRI versus cetuximab/bevacizumab + FOLFIRI in participants with KRAS/NRAS and BRAF wildtype recurrent, unresectable or metastatic colorectal cancer who have received prior chemotherapy
This clinical trial is testing a new targeted drug, amivantamab, combined with chemotherapy for people with advanced bowel cancer. Researchers want to see if this combination works better at slowing cancer growth and helping people live longer than current standard targeted treatments after their first chemotherapy has stopped working.
Recurrent, unresectable or metastatic colorectal cancerRomania - RecruitingPHASE3
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
This study looks at a new medicine called enicepatide for people who are overweight or have obesity and also have type 2 diabetes. We want to see if it helps with weight loss and if it's safe to use.
Obesity or OverweightType 2 Diabetes MellitusRomania - RecruitingPHASE3
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
This study looks at a new drug, elritercept, for people with myelofibrosis and anaemia who are already taking ruxolitinib. It compares elritercept to a dummy drug (placebo) to see if it improves anaemia and other symptoms, and how safe it is.
MyelofibrosisAnemiaRomania - Completed
Multi-centre European study of major infectious disease syndromes (MERMAIDS) – Acute respiratory infections
This study looks at acute chest and throat infections to understand why some people get much sicker than others. Researchers from the University of Oxford are collecting blood and swab samples from adults treated at GP surgeries or hospitals to help develop better, more personalised treatments for future infections.
Acute respiratory infectionsRomania - RecruitingPhase III
A study of JNJ-78934804 in participants with moderately to severely active Crohn's disease
This clinical trial is testing a new combination medicine, JNJ-78934804, for moderate to severe Crohn’s disease. It combines two drugs into one injection to target gut inflammation. Researchers want to see if this two-in-one approach works better than a single medicine for people whose previous treatments have stopped working.
Crohn’s diseaseRomania - RecruitingTherapeutic confirmatory (Phase III)
KontRASt-02: A randomized, controlled, open label, phase III study evaluating the efficacy and safety of JDQ443 versus docetaxel in previously treated subjects with locally advanced or metastatic KRAS G12C mutant non-small cell lung cancer.
This clinical trial compares a new targeted drug called JDQ443 with standard chemotherapy (docetaxel). It is for adults with advanced non-small cell lung cancer that carries a specific genetic change called KRAS G12C. Researchers want to find out which treatment keeps cancer from growing for longer.
Advanced non-small cell lung cancer harboring the KRAS G12C mutationRomania - AuthorisedTherapeutic confirmatory (Phase III)
A Long-term Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
This study tests an inhaled dry powder medicine called treprostinil palmitil for adults with high blood pressure in the lungs linked to lung scarring. The trial lasts up to two years to see if the medicine is safe and helps improve breathing, walking ability, and overall quality of life.
Pulmonary Hypertension Associated with Interstitial Lung DiseaseRomania - AuthorisedTherapeutic exploratory (Phase II)
A Phase 2 Randomized, Double-blind, Placebo-Controlled Study to Assess the Safety and Efficacy of MTX-474 in the Treatment of Participants with Diffuse Cutaneous Systemic Sclerosis (dcSSc)
This study tests a new medicine called MTX-474 for adults with diffuse cutaneous systemic sclerosis. This rare condition causes skin thickening and hardening across the body. Researchers want to see if MTX-474 is safe and if it helps soften the skin over 24 weeks compared to a dummy treatment.
Diffuse Cutaneous Systemic Sclerosis (dcSSc)Romania - AuthorisedTherapeutic confirmatory (Phase III)
A Phase 3b, Open-Label Study of Crinecerfont to Evaluate Androgen Reduction and Related Outcomes in Adults With Classic Congenital Adrenal Hyperplasia
This clinical trial is studying a medicine called crinecerfont for adults with classic congenital adrenal hyperplasia (CAH). CAH causes the body to make too much male hormone. Researchers want to see if this daily medicine can safely lower these hormone levels over 24 weeks without needing high steroid doses.
Classic Congenital Adrenal Hyperplasia (CAH)Romania - AuthorisedTherapeutic exploratory (Phase II)
Randomized, Double blind, Phase II Trial of Vortosiran to Evaluate Safety, Tolerability, and Pharmacodynamic Efficacy in Participants with Prior Venous Thromboembolism After Completion of Initial Anticoagulant Therapy (Cohort A) and in Cancer Patients at High Risk of Venous Thromboembolism (Cohort B)
This study tests a new injection called vortosiran to see if it can safely prevent blood clots. It is for adults who have had a blood clot in the past, or people with cancer who have a high risk of getting one. Researchers want to see how it affects clotting proteins.
Venous ThromboembolismRomania - AuthorisedTherapeutic exploratory (Phase II)
A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Participants with Sjogren’s Disease-Associated Sensorimotor or Sensory Polyneuropathy
This study tests a medicine called Vyvgart in adults with Sjögren's disease who have nerve damage in their hands, legs, or feet. Researchers want to see if regular injections under the skin can ease nerve symptoms, reduce fatigue, and be used safely compared with a dummy treatment.
Sjogren’s Disease-Associated Sensorimotor Polyneuropathy (SMPN) or Sensory Polyneuropathy (SPN)Romania - AuthorisedTherapeutic exploratory (Phase II)
A Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long Term Safety and Tolerability of KT-621 in Participants With Asthma Previously Enrolled in a KT-621 Asthma Study
This study looks at the long-term safety of a new medicine called KT-621 for adults with moderate to severe eosinophilic asthma. It is an extension study for people who already took part in an earlier KT-621 trial, checking how well the body tolerates the treatment over 52 weeks.
Uncontrolled Moderate to Severe Eosinophilic AsthmaRomania - AuthorisedTherapeutic confirmatory (Phase III)
A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination with the Modified Gemcitabine and nab-Paclitaxel Regimen Versus the Standard Gemcitabine and nab-Paclitaxel Regimen for the Treatment of Patients with Metastatic Pancreatic Ductal Adenocarcinoma Cancer (MAPKeeper 301)
This clinical trial is testing a new targeted medicine called atebimetinib for advanced pancreatic cancer. Doctors want to see if adding this drug to standard chemotherapy helps people live longer and improves their quality of life compared to standard chemotherapy alone.
Metastatic Pancreatic Ductal AdenocarcinomaRomania - AuthorisedTherapeutic confirmatory (Phase III)
LUMIOS - A Phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group trial to assess the efficacy, safety and tolerability of cenerimod in adult patients with systemic lupus erythematosus and active lupus nephritis in combination with background therapy
This study tests a new medicine called cenerimod for adults with lupus and active kidney inflammation (lupus nephritis). Researchers want to see if adding cenerimod to standard treatments helps protect the kidneys, reduces protein in the urine, and lowers the need for steroid medicines over 76 weeks.
Systemic lupus erythematosus and active lupus nephritisRomania - AuthorisedTherapeutic exploratory (Phase II)
A Randomized, Double-Blind, Placebo-controlled, Parallel Arm, 52-week Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of Two Doses of EXPD-101 in Participants with COPD
This 52-week clinical study is testing an experimental medicine called EXPD-101 for adults living with COPD. Researchers want to find out if taking this treatment can safely reduce chest flare-ups, ease breathing symptoms, and help people stay out of hospital compared with a dummy treatment (placebo).
Chronic Obstructive Pulmonary Disease (COPD) exacerbationsRomania - AuthorisedTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, DoubleBlind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Arterial Hypertension (PALM-PAH)
This study is testing a new once-daily dry powder inhaler called treprostinil palmitil for pulmonary arterial hypertension (high blood pressure in the lungs). Doctors want to see if inhaling this medicine once a day helps people walk further and improves their daily symptoms compared with a dummy medicine (placebo).
Pulmonary Arterial HypertensionRomania - AuthorisedTherapeutic confirmatory (Phase III)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Telitacicept in Adult Participants with Active Primary Sjögren’s Disease
This study tests a new injection called telitacicept for adults with active primary Sjögren's disease. Researchers want to see if this medicine works better and is safer than a dummy treatment (placebo) at lowering general disease activity, easing dryness, and improving daily symptoms over 48 weeks.
Active Primary Sjögren’s DiseaseRomania - AuthorisedPhase II and Phase III (Integrated)
An Operationally Seamless Phase 2/3 Randomized, Open-label, Active-Controlled Study Evaluating the Safety and Efficacy of an Injectable Regimen of GS-3242 in Combination with Lenacapavir Versus Biktarvy (Bictegravir/Emtricitabine/Tenofovir Alafenamide) in Treatment-Naive People With HIV-1
This clinical trial looks at a new long-acting injection for adults with HIV-1 who have not started treatment before. It compares an injectable combination of two medicines, GS-3242 and lenacapavir, against a standard daily tablet called Biktarvy. The goal is to see if injections work just as well as daily pills.
human immunodeficiency virus type 1 (HIV-1)Romania - AuthorisedHuman Pharmacology (Phase I)- Bioequivalence Study
An open label, balanced, randomized, two-treatment, four-period, two-sequence, single-dose, crossover fully replicate bioequivalence study comparing Mesalamine delayed release capsules 400 mg, manufactured by Sun Pharmaceutical Industries Limited, India with Mesalamine Delayed-Release Capsules 400 mg, manufactured for Teva Pharmaceuticals USA, Inc. Parsippany, NJ 07054, in healthy, adult, human subjects under fed condition.
This study tests whether a generic version of mesalamine, a medicine for ulcerative colitis, behaves the same way in the body as an existing brand. Healthy adult volunteers will take a single capsule after eating a meal, and blood samples will track how the medicine is absorbed.
Ulcerative colitisRomania - RecruitingTherapeutic confirmatory (Phase III)
A Phase IIIb Randomised, Parallel-Group, Double-Blind, Placebo-Controlled, Two-Arm Study to Evaluate the Effect of Elafibranor 80 mg on Normalisation of Alkaline Phosphatase in Adult Participants with Primary Biliary Cholangitis (PBC) and Inadequate Response or Intolerance to Ursodeoxycholic Acid
This study is testing a medicine called elafibranor for adults with primary biliary cholangitis (PBC). It is for people whose regular treatment has not worked well enough or caused side effects. Researchers want to see if elafibranor can safely bring liver test results back to normal, healthy levels.
Primary Biliary Cholangitis (PBC)Romania - RecruitingTherapeutic confirmatory (Phase III)
A Phase 3, 52-Week, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab in Adult Subjects With Prurigo Nodularis Who are Inadequately Controlled on Topical Therapies or Not Eligible for Topical Therapies
This study tests whether a new medicine called rocatinlimab helps adults with prurigo nodularis. This skin condition causes intensely itchy, firm lumps to form on the skin. The trial checks if the treatment can reduce severe itching and heal skin bumps when prescription creams have not provided enough relief.
Prurigo NodularisRomania - RecruitingTherapeutic confirmatory (Phase III)
An Extension Study to Evaluate the Long-Term Outcomes of Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe-ROP-1920 Study
This study follows children who received eye treatment for retinopathy of prematurity (ROP) in an earlier trial. Researchers want to see how their eyesight, eye structure, and general development progress as they grow up. The goal is to ensure the treatment is safe and effective in the long run.
Retinopathy of prematurity (ROP)Romania - RecruitingTherapeutic confirmatory (Phase III)
A Randomized, Double-Blind, Dose Finding and Comparison Study of the Safety and Efficacy of High Doses of Eteplirsen, Preceded by an Open-Label Dose Escalation, in Patients with Duchenne Muscular Dystrophy With Deletion Mutations Amenable to Exon 51 Skipping
This clinical trial is testing whether higher doses of a medicine called eteplirsen are safe and helpful for boys with Duchenne muscular dystrophy. It is for males with a specific genetic change that can be treated by skipping exon 51, aiming to protect muscle strength over nearly three years.
Duchenne Muscular DystrophyRomania - RecruitingTherapeutic exploratory (Phase II)
A Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Regimens Containing VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects with Chronic Hepatitis B Virus Infection
This clinical study tests new treatments for chronic hepatitis B, a long-term liver infection. Researchers want to see if combining experimental medicines with an existing drug called interferon can safely lower the amount of virus in the body, working towards a long-lasting cure without needing daily tablets for life.
Chronic Hepatitis B Virus InfectionRomania - RecruitingTherapeutic confirmatory (Phase III)
ATHENA (A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)
This study looks at two medicines, rucaparib and nivolumab, for women with advanced ovarian, fallopian tube, or primary peritoneal cancer. It aims to see if using these drugs after standard chemotherapy helps keep the cancer away for longer compared to dummy treatments, known as placebos.
Ovarian epithelialcancer, Malignant peritonealneoplasm, advanced (FIGO stage III-IV), high-grade epithelial ovarian, fallopiantube, or primary peritoneal cancer (who responded to front-lineRomania - RecruitingTherapeutic confirmatory (Phase III)
A Phase 3, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-103, a Novel Formulation of UGN-102, for the Treatment of Patients With Low Grade (LG) Nonmuscle Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of Recurrence (UTOPIA)
This phase 3 study tests a new treatment called UGN-103 for non-muscle invasive bladder cancer. UGN-103 is a medicine placed directly into the bladder to help clear early-stage cancer cells. Researchers want to see how well it works, how safe it is, and if it can reduce the need for surgery.
Nonmuscle Invasive Bladder CancerRomania - RecruitingTherapeutic confirmatory (Phase III)
Efficacy and safety of co-administered cagrilintide and semaglutide (CagriSema) 1.0 mg/1.0 mg s.c. once weekly versus tirzepatide 5 mg s.c. once weekly in participants with type 2 diabetes inadequately controlled on metformin, SGLT2 inhibitor or both
This study compares two weekly injectable medicines for type 2 diabetes: a new combined treatment called CagriSema and an existing medicine called Mounjaro (tirzepatide). Researchers want to see which treatment is better at lowering average blood sugar levels and helping people manage their body weight over 60 weeks.
Type 2 DiabetesRomania - RecruitingTherapeutic exploratory (Phase II)
A Phase 2, multinational, multicenter, randomized, double blind, placebo controlled, dose-ranging study to evaluate the efficacy and safety of SAR441566 in adults with moderate to severe Crohn’s disease.
This clinical study tests a new medicine called balinatunfib (SAR441566) for adults with moderate to severe Crohn's disease. Researchers want to see if different doses help heal the bowel lining and reduce symptoms compared to a dummy treatment (placebo), while checking for any unwanted side effects.
Crohn's diseaseRomania - RecruitingTherapeutic exploratory (Phase II)
A randomized, double blind, placebo controlled, Proof of Concept (PoC) study to assess the efficacy, safety and tolerability of itepekimab in participants with inadequately controlled chronic rhinosinusitis without nasal polyps
This clinical trial is testing a new medicine called itepekimab for adults with ongoing sinus swelling that has not cleared up with standard treatments. Researchers want to find out if the medicine can safely reduce inflammation inside the sinuses, clear blockages seen on CT scans, and relieve everyday nasal symptoms.
Respiratory tract diseasesRomania - RecruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Orally Administered Deucrictibant Extended-release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults with Hereditary Angioedema
This clinical trial is testing a new daily tablet called deucrictibant for adults with hereditary angioedema (HAE). Researchers want to find out if taking this tablet can safely prevent painful swelling attacks. Participants will take either the study tablet or an inactive dummy pill for 24 weeks.
Hereditary AngioedemaRomania - RecruitingTherapeutic confirmatory (Phase III)
A Phase 3 Randomized, Double-Blinded, Placebo-Controlled Multicenter Trial with Open-Label Extension to Evaluate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjögren’s Disease
This study tests whether a medicine called efgartigimod can help adults with primary Sjögren’s disease. Researchers want to see if regular injections under the skin can ease symptoms like joint pain, dry eyes, and dry mouth, and lower overall body inflammation compared with a dummy treatment (placebo).
Primary Sjögren’s DiseaseRomania - RecruitingTherapeutic exploratory (Phase II)
A Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of KBP-336 as an Adjunct to Diet and Exercise in Obese Individuals with Osteoarthritis of the Knee
This clinical trial is testing a new medicine called KBP-336 for adults living with obesity and knee osteoarthritis. Alongside a healthy diet and exercise, researchers want to see if KBP-336 helps reduce body weight and eases knee pain over six months, compared to an inactive dummy treatment (placebo).
Obesity, Knee osteoarthritisRomania - AuthorisedTherapeutic confirmatory (Phase III)
A Master Protocol for a Phase 3, Randomized, Multicenter, Double-blind Study to Assess Stroke and Systemic Embolism Prevention with REGN7508 and REGN9933, Monoclonal Antibodies Against Factor XI, versus Placebo in Participants with Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable (ROXI-INCLINE)
This clinical study tests two new medicines, REGN7508 and REGN9933, for adults with atrial fibrillation (an irregular heartbeat). It aims to find out if these treatments can safely stop blood clots and strokes in people who cannot take standard blood-thinning tablets due to a high risk of bleeding.
Atrial Fibrillation (AF)Romania - RecruitingTherapeutic confirmatory (Phase III)
2-year, Multicentre, Open-label, Flexible-dose Study to Evaluate the Safety and Tolerability of Cariprazine in the Treatment of Adolescent Patients with Schizophrenia
This two-year study looks at the safety of a medicine called cariprazine (Reagila) in teenagers aged 13 to 17 with schizophrenia. Researchers want to see how well young people tolerate the drug, monitor any side effects, and check if it helps improve their symptoms over time.
Adolescent patient (13-17 years of age) with SchizophreniaRomania - RecruitingTherapeutic exploratory (Phase II)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma
This study is testing a new medicine called rocatinlimab for adults with moderate-to-severe asthma. Researchers want to find the best dose and see if it cuts down asthma attacks that need steroid tablets or hospital care, while checking how safe and effective it is compared with a dummy medicine.
Moderate-to-severe AsthmaRomania - RecruitingTherapeutic confirmatory (Phase III)
Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults with Severe Hypertriglyceridemia (SHASTA-3 Study)
This study tests a new injection called plozasiran for adults with very high blood fat levels, known as severe hypertriglyceridemia. Researchers want to see if the medicine can safely lower blood fats over one year compared to a dummy jab, reducing the risk of serious problems like pancreas inflammation.
Severe hypertriglyceridemia (SHTG)Romania - RecruitingTherapeutic confirmatory (Phase III)
A Double-Blind, Randomized, Active-Controlled, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P51 and Keytruda in Combination with Platinum-Pemetrexed Chemotherapy in Patients with Previously Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer
This study tests a new medicine called CT-P51 compared to an established treatment, Keytruda, for advanced non-small cell lung cancer. Both medicines are given with standard chemotherapy. The aim is to see if CT-P51 works just as well and is just as safe as Keytruda for newly diagnosed patients.
Previously Untreated Metastatic Non-Squamous Non-Small Cell Lung CancerRomania - RecruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multicenter, Open-Label, Long-Term Trial to Evaluate the Safety and Efficacy of Efgartigimod (ARGX-113) PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
This study looks at a medicine called efgartigimod for adults with primary immune thrombocytopenia (ITP). ITP causes low blood platelets, leading to easy bruising and bleeding. Researchers want to see if an injection under the skin is safe and helps keep platelet counts at a healthy level over time.
Primary Immune ThrombocytopeniaRomania - RecruitingHuman Pharmacology (Phase I)- Bioequivalence Study
Assessment of Pharmacokinetic Similarity of FYB206 in Comparison with Keytruda in Resected Stage II or Stage III Melanoma Patients
This study tests a new medicine called FYB206 for adults who have had advanced skin cancer (melanoma) removed by surgery. Researchers want to check if FYB206 behaves in the body in the exact same way as Keytruda, an approved immunotherapy drug used to help stop cancer returning.
Melanoma: Adjuvant treatment of patients with Stage IIB, IIC, or III melanoma following complete resectionRomania - RecruitingTherapeutic confirmatory (Phase III)
A Randomized, Open-Label, Multicenter Phase 3 Trial of Domvanalimab, Zimberelimab, and Chemotherapy Versus Nivolumab and Chemotherapy in Participants with Previously Untreated Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma
This phase 3 clinical trial is looking at a new combination of immunotherapy drugs given alongside chemotherapy. It aims to find out if this new combination helps people with untreated, advanced cancer of the stomach or food pipe live longer compared to the current standard immunotherapy and chemotherapy treatment.
Metastatic Esophageal or Gastric Cancer, Esophageal or Gastric CancerRomania - RecruitingTherapeutic confirmatory (Phase III)
A randomized, double-blind, placebo controlled, 3-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjögren’s syndrome (NEPTUNUS-2)
This study tests a new medicine called ianalumab for adults with active Sjögren's syndrome. Researchers want to see if regular injections can calm the immune system, ease severe tiredness, and improve dry eyes and mouth compared to a dummy jab (placebo) over 48 weeks of treatment.
Sjögren’s SyndromeRomania - RecruitingTherapeutic confirmatory (Phase III)
A multicenter, open-label, single-arm study to evaluate long-term safety and tolerability of brivaracetam in study participants with childhood absence epilepsy or juvenile absence epilepsy
This study looks at the long-term safety of an epilepsy medicine called brivaracetam. It is for adults living with childhood or juvenile absence epilepsy, a condition causing brief daydream-like pauses. Researchers want to see how well patients tolerate the medicine and track any side effects over time.
Childhood Absence Epilepsy, Juvenile Absence EpilepsyRomania - AuthorisedPhase I and Phase II (Integrated)- Other
ROSETTA RCC-208: A Phase 1/2 Open-label, Multi-center, Randomized Study of Pumitamig Alone or in Combination with Ipilimumab or Cabozantinib in Participants with Advanced Renal Cell Carcinoma (RCC)
This study is testing an experimental medicine called pumitamig for adults with advanced kidney cancer. Doctors want to see how safe it is on its own or alongside other cancer drugs, and whether it can help shrink tumours or stop the cancer from getting worse.
Advanced Renal Cell CarcinomaRomania - RecruitingHuman Pharmacology (Phase I)- Other
A clinical study of MK-4646 in people with HIV (MK-4646-003)
This early-stage clinical study looks at an experimental medicine called MK-4646 in adults living with HIV. Researchers want to find out how safe the medicine is, how the body handles it, and what side effects it might cause. It is open to adults aged 18 and older.
HIV infectionRomania - AuthorisedTherapeutic confirmatory (Phase III)
A Randomized, Double-Blind, Head-to-Head Phase 3 Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone at 52 Weeks in Adults with Idiopathic Pulmonary Fibrosis (SURPASS-IPF)
This study tests a new medicine called LYT-100 for idiopathic pulmonary fibrosis (IPF). Researchers want to see if it works as well as or better than pirfenidone, an existing treatment, to protect lung capacity over one year. It is open to adults aged 18 and older with IPF.
Idiopathic Pulmonary FibrosisRomania - AuthorisedTherapeutic confirmatory (Phase III)
A Phase 3, Double-Blind, Randomized Trial Evaluating the Efficacy and Safety of Elritercept (TAK‑226) Compared to Placebo in Participants With Myelofibrosis and Anemia on Concurrent Ruxolitinib Therapy
This study looks at whether an experimental medicine called elritercept can help people with myelofibrosis who have anaemia. Researchers want to see if taking elritercept alongside an existing medicine called ruxolitinib helps reduce or stop the need for regular blood transfusions and improves energy levels.
MyelofibrosisRomania - RecruitingTherapeutic exploratory (Phase II)
A Phase 2, multinational, multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of SAR441566 in adults with moderate-to-severe ulcerative colitis
This study tests an experimental medicine called SAR441566 for adults with moderate-to-severe ulcerative colitis. Researchers want to see if different doses of this treatment can safely reduce bowel inflammation, relieve painful symptoms, and help bring the condition into remission compared to an inactive dummy treatment (a placebo).
Colitis UlcerativeRomania - RecruitingHuman Pharmacology (Phase I)- Bioequivalence Study
An open label, balanced, randomized, two-treatment, four-period, two-sequence, single-dose, crossover fully replicate bioequivalence study comparing Mesalamine delayed release capsules 400 mg manufactured by Sun Pharmaceutical Industries Limited, India with Mesalamine Delayed-Release Capsules 400 mg, manufactured for Teva Pharmaceuticals USA, Inc. Parsippany, NJ 07054, in healthy, adult, human subjects under fasting condition.
This trial tests whether two different brands of mesalamine capsules work identically in the body. Mesalamine is a common medicine used to treat ulcerative colitis. Healthy adult volunteers will take single doses of each brand while fasting, allowing researchers to measure and compare how the medicine is absorbed.
ulcerative colitisRomania - RecruitingTherapeutic confirmatory (Phase III)
A randomized, phase 3, double-blind, double-dummy, active comparator-controlled multicenter study to evaluate the efficacy and safety of 2 doses of linaprazan glurate compared to lansoprazole in 4 or 8 weeks healing in participants with erosive esophagitis (EE) due to gastroesophageal reflux disease (GERD) of Los Angeles (LA) grades A to D
This study tests a new medicine called linaprazan glurate for severe acid reflux. Researchers want to see if it heals damage in the food pipe better than lansoprazole, a standard NHS treatment. It compares how well both medicines soothe heartburn and repair the lining of the gullet over 8 weeks.
Erosive esophagitis (EE) due to gastroesophageal reflux disease (GERD)Romania